Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Proteogenomics-Driven Targeted Therapy Basket Trial (No. 3-1 Gamma IFN Subprotocol)
KCT0012307Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), gastric cancer (GC), esophageal cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on KCT0012307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012307.